Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (244)	12/7/1997 1:46:00 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

I am not surprised, but I am gravely disappointed that Ivax lacks the organizational forethought to get Paxene to the market in a timely manner. It seems to me that if BM-S's exclusive rights for paclitaxel's use in breast cancer were to expire in December, then I have to question why Ivax did not focus on Paxene's use against breast cancer instead of K-S. Could the answer be that Paxene is no better than Paclitaxel against breast cancer? Or is it that our Ivax management is not thinking? Thanks for the news. You are a good corroborator. Jackson